Home - Products - Apoptosis - IL Receptor - NFAT inhibitor, Cell Permeable

NFAT inhibitor, Cell Permeable

CAS No. 592517-80-1

NFAT inhibitor, Cell Permeable( —— )

Catalog No. M30612 CAS No. 592517-80-1

NFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    NFAT inhibitor, Cell Permeable
  • Note
    Research use only, not for human use.
  • Brief Description
    NFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
  • Description
    NFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
  • In Vitro
    11R-VIVIT (100 nM) shows a significant reduction of NFAT2 expression in high glucose treated podocytes compared to podocytes treated with normal glucose. 11R-VIVIT attenuates high glucose induced filtration barrier dysfunction of podocytes.
  • In Vivo
    11R-VIVIT significantly abrogates the increased urinary albumin excretion rates, attenuates glomerular basement membrane (GBM) thickening and podocyte foot process effacement, partially restores podocyte number, inhibits NFAT2 activation and uPAR expression in glomerular podocytes.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    592517-80-1
  • Formula Weight
    3573.15
  • Molecular Formula
    C147H259N67O36S
  • Purity
    >98% (HPLC)
  • Solubility
    water:1 mg/mL
  • SMILES
    [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Elloumi et al (2012) A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis. PLoS One 7 e34172 PMID:
molnova catalog
related products
  • Risankizumab

    Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.

  • Abrezekimab

    Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13.

  • Dersalazine

    Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.